Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joyce Liu

Showing results (81-90 of 128) with videos related to

Pageof 13
Sort By:
Cancer Research|December 1, 2017
Photodynamic Priming Mitigates Chemotherapeutic Selection Pressures and Improves Drug DeliveryHuang-Chiao Huang, Imran Rizvi, Joyce Liu, et al.
Chembiochem : a European Journal of Chemical Biology|December 28, 2018
Identifying the Biosynthetic Gene Cluster for Triacsins with an N-Hydroxytriazene MoietyFrederick F Twigg, Wenlong Cai, Wei Huang, et al.
Bioengineering & Translational Medicine|June 29, 2019
Layer-by-layer nanoparticles for novel delivery of cisplatin and PARP inhibitors for platinum-based drug resistance therapy in ovarian cancerLawrence B Mensah, Stephen W Morton, Jiahe Li, et al.
Neoplasia (New York, N.Y.)|February 4, 2010
Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survivalAdam Clauss, Vivian Ng, Joyce Liu, et al.
Molecular Metabolism|November 27, 2019
Subcellular metabolic pathway kinetics are revealed by correcting for artifactual post harvest metabolismSophie Trefely, Joyce Liu, Katharina Huber, et al.
Plos One|November 23, 2013
Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutationsNicolai Juul Birkbak, Bose Kochupurakkal, Jose M G Izarzugaza, et al.
Cancer Research|August 16, 2022
Targeting DNA Repair with Combined Inhibition of NHEJ and MMEJ Induces Synthetic Lethality in TP53-Mutant CancersJeffrey Patterson-Fortin, Arindam Bose, Wei-Chih Tsai, et al.
International Journal of Clinical Oncology|November 7, 2022
A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumorsSusana Campos, Ursula Matulonis, Suzanne Berlin, et al.
Journal of Medicinal Chemistry|September 28, 2023
The Importance of Tracking "Missing" Metabolites: How and Why?Shuai Wang, T Eric Ballard, Lisa J Christopher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancerMichael J Callahan, Zoltan Nagymanyoki, Tomas Bonome, et al.
Pageof 13

Showing results (81-90 of 128) with videos related to

Sort By:
Pageof 13
Cancer Research|December 1, 2017
Photodynamic Priming Mitigates Chemotherapeutic Selection Pressures and Improves Drug DeliveryHuang-Chiao Huang, Imran Rizvi, Joyce Liu, et al.
Chembiochem : a European Journal of Chemical Biology|December 28, 2018
Identifying the Biosynthetic Gene Cluster for Triacsins with an N-Hydroxytriazene MoietyFrederick F Twigg, Wenlong Cai, Wei Huang, et al.
Bioengineering & Translational Medicine|June 29, 2019
Layer-by-layer nanoparticles for novel delivery of cisplatin and PARP inhibitors for platinum-based drug resistance therapy in ovarian cancerLawrence B Mensah, Stephen W Morton, Jiahe Li, et al.
Neoplasia (New York, N.Y.)|February 4, 2010
Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survivalAdam Clauss, Vivian Ng, Joyce Liu, et al.
Molecular Metabolism|November 27, 2019
Subcellular metabolic pathway kinetics are revealed by correcting for artifactual post harvest metabolismSophie Trefely, Joyce Liu, Katharina Huber, et al.
Plos One|November 23, 2013
Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutationsNicolai Juul Birkbak, Bose Kochupurakkal, Jose M G Izarzugaza, et al.
Cancer Research|August 16, 2022
Targeting DNA Repair with Combined Inhibition of NHEJ and MMEJ Induces Synthetic Lethality in TP53-Mutant CancersJeffrey Patterson-Fortin, Arindam Bose, Wei-Chih Tsai, et al.
International Journal of Clinical Oncology|November 7, 2022
A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumorsSusana Campos, Ursula Matulonis, Suzanne Berlin, et al.
Journal of Medicinal Chemistry|September 28, 2023
The Importance of Tracking "Missing" Metabolites: How and Why?Shuai Wang, T Eric Ballard, Lisa J Christopher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancerMichael J Callahan, Zoltan Nagymanyoki, Tomas Bonome, et al.
Pageof 13